Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development for autoimmune type 1 diabetes. The executed agreement is valued at approximately $50M, of which $36M is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142’s ongoing clinical program and commercial manufacturing services upon regulatory approval.